Try our beta test site
128 studies found for:    "Measles"
Show Display Options
Rank Status Study
21 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
22 Completed Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
Conditions: Rubella;   Measles
Intervention: Biological: Double viral (MR) vaccine
23 Unknown  Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Measles
Intervention: Biological: attenuated measles vaccine
24 Completed A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
Conditions: HIV Infections;   Measles
Interventions: Biological: Attenuvax;   Biological: M-M-R-II
25 Completed Impact of HIV on Measles and Measles Immunisation
Conditions: HIV Infection;   Measles;   Children
Intervention: Biological: standard-titer measles vaccine
26 Active, not recruiting Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
Conditions: Measles;   Rubella;   Mumps
Intervention: Biological: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
27 Completed Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
28 Completed Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
29 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
30 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: M-M-R®II;   Biological: Kinrix®;   Biological: Varivax®
31 Completed Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines
Conditions: Measles;   Rubella;   Japanese Encephalitis
Interventions: Biological: Measles-Rubella combined vaccine(MR);   Biological: Japanese Encephalitis alive vaccine(JE)
32 Completed Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
Conditions: Mumps;   Rubella;   Measles
Intervention: Biological: MMR (Mumps, Measles and Rubella)
33 Completed Coadministration of Measles-rubella and Rotavirus Vaccines
Conditions: Measles Antibody Seroconversion;   Rubella Antibody Seroconversion;   Rotavirus GMT;   Rotavirus IgA Seropositivity
Interventions: Biological: Rotarix vaccine;   Biological: measles-rubella vaccine
34 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Measles;   Rubella;   Mumps;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
35 Completed Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Rubella;   Measles;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
36 Completed Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
37 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Varicella;   Rubella;   Measles
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
38 Completed Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine);   Biological: GSK Biologicals' 208136, new formulation
39 Completed
Has Results
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Conditions: Japanese Encephalitis;   Measles;   Mumps;   Rubella
Intervention: Biological: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
40 Completed Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: PriorixTM;   Biological: VarilrixTM;   Biological: GSK Biologicals' vaccine 208136

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.